Financial Results : Avalon Pharma Q1 2025 earnings soar 107% to SAR 19.4M

Avalon Pharma Q1 2025 earnings soar 107% to SAR 19.4M

12/05/2025 Argaam Exclusive

View other reports

Middle East Pharmaceutical Industries Co. (Avalon Pharma) reported a net profit of SAR 19.4 million in the first quarter of 2025, soaring 107% from SAR 9.4 million a year earlier.



Current Quarter Comparison (M)

Compared With The
Item Q1 2024 Q1 2025 Change‬
Revenues 75.82 97.36 28.4 %
Gross Income 45.30 60.27 33.0 %
Operating Income 12.32 22.40 81.8 %
Net Income 9.37 19.40 107.1 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyal) 0.47 0.97 107.1 %
EPS (Riyal) 0.47 0.97 107.1 %

This was buoyed by a 28% leap year-on-year (YoY) in revenues to SAR 97.4 million, as well as attraction of new customers and launch of new products. However, this was offset by higher general, administrative, selling, and administrative expenses.

 

Sequentially, the company’s profit fell 56.7% from SAR 44.8 million in Q4 2024, hurt by lower revenues.

 

Shareholders’ equity, no minority interest, reached SAR 387.6 million as of March 31, 2025, up from SAR 315.5 million a year earlier.

 

Attached Documents:

 

View More Financial Results

 

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.